Objective: Diabetes is highly prevalent in individuals with acute coronary syndrome (ACS). Current NICE guidelines recommend diabetes screening of hyperglycaemic patients using a fasting plasma glucose after 4 days from admission. In 2012 the World Health Organisation (WHO) approved the use of HbA 1c in the diagnosis and targeted screening for type 2 diabetes. We introduced a service improvement project using HbA 1c for diabetes screening in patients with no previous diagnosis of diabetes admitted with ACS regardless of glycaemic state.
INTRODUCTION
Diabetes mellitus is a significant public health challenge associated with cardiovascular morbidity and mortality. 1 The prevalence of diabetes in Northern Ireland is currently around 5.3%, with new diagnoses increasing by around 33% in the past 5 years. 2 It is estimated that up to 12,000 individuals within the region with diabetes remain undiagnosed.
2 A targeted programme of diabetes screening, particularly for those with established cardiovascular disease is recommended to identify and treat individuals at high risk.
Coronary heart disease is a leading cause of morbidity and mortality in diabetes, and around 22-27% of patients admitted with acute coronary syndrome (ACS), have established diabetes. 3, 4, 5, 6 As in the general population, unrecognised diabetes is an unmet need for up to 22-31% of others presenting with ACS. 3, 4, 5, 6 NICE (National Institute for Health and Care Excellence) guidelines for diabetes screening recommend that all patients with admission blood glucose concentrations above 11.0 mmol/l should have a fasting plasma glucose no earlier than day 4 after ACS onset or have an HbA 1c test before discharge.
1
The WHO have recommended HbA 1c as the preferred screening test for the diagnosis of type 2 diabetes mellitus. 6 Others have highlighted the potential role for HbA 1c as a universal screening test in the ACS setting. 7 More recently the ESC/EASD (European Society of Cardiology/European Association for the Study of Diabetes) have recommended all ACS patients be screened for diabetes. 8 We undertook a retrospective audit of NICE diabetes screening guidelines followed by a service improvement project assessing the utility of universal HbA 1c screening in the ACS population.
METHODS

Audit
The Myocardial Ischaemia National Audit Project (MINAP) is a clinical database, for collection of clinical data on all patients admitted with ACS. 420 patients who presented to the Mater Hospital were identified using the MINAP database 
Service Improvement Project
HbA 1c testing was recommended for screening in ACS regardless of glycaemic status during a service improvement project.
No patients tested were known to have medical conditions that could influence HbA 1c measurement. This included factors that affect erythropoiesis such as iron or B12 deficiency or supplementation, haemoglobinopathies and conditions that affect erythocyte life span such as splenectomy or splenomegaly. 6 Patients were not screened for chronic aspirin use which may cause a falsely low HbA 1c in certain assays. 6 We categorised patients according to WHO criteria as "probable diabetes" (HbA 1c >48 mmol/mol), "high risk" (HbA 1c 42-47 mmol/mol) and "not diabetes" (HbA 1c <42 mmol/mol). 6, 7 
RESULTS
Over the previous 21 month period 93 of 420 (22%) ACS patients were identified with established diabetes. Of the remaining 327 patients, only 8 (2.4%) met NICE criteria for diabetes screening and only one patient was tested (Figure 1 ).
During the service improvement phase, 17 of 66 ACS patients had established diabetes. Of the remaining 49 patients only 2 met criteria for screening and neither had fasting glucose tested. 26 of 49 patients (52%) were tested with a mean HbA 1c level of 45.1 mmol/mol (range 31.1-65.0 mmol/mol). 7/26 (26.9%) of these were categorised as "probable diabetes", 10/26 (38.4%) were at high risk of developing diabetes and 9/26 (34.6%) had diabetes excluded (Figure 2 ).
DISCUSSION
Diabetes mellitus is increasingly prevalent and is a significant public health challenge. 2, 6 Diabetes is associated with increased cardiovascular risk, and in patients presenting with acute coronary syndrome; it is an independent predictor of mortality and is associated complications including heart failure and bleeding. 8 For these reasons, the European Society of Cardiology (ESC) recommend that all patients admitted with ACS are screened for diabetes and have recently recommended the adoption of HbA 1c as a screening tool in line with the World Health Organisation.
8
Targeted diabetes screening as advocated by NICE using hyperglycaemia as an inclusion criterion appeared to lack sensitivity and was not readily implemented in clinical practice during our recent audit. Use of universal HbA 1c screening on admission appeared to be more practical and effective with improved detection rates in this setting. In our service improvement project we identified a higher prevalence of probable diabetes and pre-diabetes cases (65.4%) compared with earlier published series. 3, 4, 5, 6 We detected a prevalence rate of established diabetes of around 22%, which is similar to earlier published reports. 3, 4, 5 Poor utilisation of current NICE screening may reflect the guidelines complexity, limited awareness and the small numbers of qualifying patients. In addition, patients may not be screened with day four fasting glucose measurement due to increasingly shorter length of stays.
There are a number of potential benefits in using HbA 1c as a screening tool for diabetes. Firstly, it is less likely to be impacted by short term fluctuations in glycaemic control, including stress hyperglycaemia. While HbA 1c testing is more expensive (£6.81) than fasting plasma glucose (£2.05) it compares favourably to the cost of an oral glucose tolerance test at £7.48. 9 HbA 1c testing is not recommended for screening in type 1 diabetes, secondary diabetes or pregnancy. In these scenarios, established fasting plasma glucose and/or glucose tolerance testing criteria remain valid and are recommended for use. Other confounders include alcoholism, chronic renal failure and conditions affecting erythropoesis. 6 This study has a number of limitations. As this was an audit and service improvement project it was not designed to determine sensitivity and specificity against a gold standard test. Despite staff education a significant proportion of This service improvement project revealed a missed population of patients with "probable diabetes" (26.9%) and at "high risk" (38.4%) of diabetes who were largely previously unscreened when NICE guidance was followed ( Figure 3 ). We believe that introduction of HbA 1c as part of an ACS admission profile offers a simplified and accessible screening test for the early diagnosis and management of patients with diabetes. Perhaps it is time for a reappraisal of UK guidelines?
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